Roche
Search results
At this year’s American Society of Retina Specialists (ASRS) annual meeting, we’re showcasing our latest research on treatment advancements for diabetic eye disease. Follow the official meeting hashtag, #ASRS2024, and read more below. Learn More. Quick Links.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 45 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.
Genentech is a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Its transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Genentech has multiple medicines for serious and life-threatening medical conditions. Access information and resources on each of our medicines.
WHY GENENTECH. We’re passionate about delivering on Our Promise to improve the lives of patients and create healthier communities for all. We foster a culture of inclusivity, integrity and creativity while boldly pursuing answers to the world’s most complex health challenges and transforming society.
Genentech is committed to defeating cancer. Building upon our legacy as pioneers in oncology, we're boldly innovating beyond the science and envision a better future for every cancer patient, caregiver, and provider. We can't do it alone.
Roche acknowledged the strength of the Genentech name to scientists, doctors and patients, rebranding its own medicines “Genentech” in the U.S. In addition, Genentech had top scientists, a streamlined decision-making process, state-of-the-art research facilities, and a robust pipeline filled with new molecules.
Learn how Genentech is continuing to go forward in the precision medicine space with real-world evidence, education for policymakers, development of molecules, education on biomarker testing and more.
